Seeing Clearer: Optimizing the Use of Vascular Endothelial Growth Factor Inhibitors in Age-related Macular Degeneration

FACULTY

David M. Brown, MD
Director, Greater Houston Retina Research Center
Clinical Professor of Ophthalmology
Baylor College of Medicine
Vice-Chair for research
Blanton Eye Institute at Houston Methodist Hospital
Houston, TX

PROGRAM OVERVIEW

This online activity targets healthcare gaps correlated with screening, multidisciplinary care and timely intervention in age-macular degeneration (AMD), which can impact vision-related quality of life.

  • By addressing these gaps, you can assess whether your approach to AMD management through screening, utilization of clinical trial data to guide appropriate treatment and multidisciplinary coordination for comprehensive AMD management – could be modified to help both strategize treatment design and close these gaps.
  • Expert discussion will guide you in identifying appropriate opportunities for early intervention, as well as assessing impact that AMD can have on vision-related quality of life.
  • You will also be immersed in dynamic whiteboard animations to memorably highlight key points related to how the inflammatory and vascular endothelial growth factor (VEGF) pathways lead to the development of AMD, as well as the fundoscopic retinal changes associated with each stage of AMD.

TARGET AUDIENCE

This activity is designed to meet the educational needs of retina specialists, ophthalmologists, optometrists, primary care providers, managed care providers, pharmacists and other healthcare providers who manage patients with age-related macular degeneration.


LEARNING OBJECTIVES

  • Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD
  • Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD
  • Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach
  • Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.


NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with age-related macular degeneration.
CNE Credits: 1.0 ANCC Contact Hour.


CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.


DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.


DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Brown discloses the following:

  • He is a consultant for Adverum Biotechnologies, Alexion Pharmaceuticals, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Genentech, Kodiak Sciences, Laboratoires Théa, Lineage Cell Therapeutics (BioTime), Novartis, Ocular Therapeutix, Optos, Regeneron Pharmaceuticals, Retinal Consultants Medical Group, Senju Pharmaceutical, and Verseon
  • He received grants from Adverum Biotechnologies, Aldeyra Therapeutics, Apellis, Bayer, Bio-Imaging Resource Center (BIRC), Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, F. Hoffmann-La Roche Limited, Gyroscope, Ionis Pharmaceuticals, Iveric Bio, Kodiak, Lowy Medical Research Institute, LumiThera, Nanoscope Therapeutics, National Eye Institute/National Institutes of Health, NGM Biopharmaceuticals, Novartis, OIRRC, Optos, Oxurion, Regeneron Pharmaceuticals, REGENXBIO, Samchundang Pharm, Santen Pharmaceutical, and Senju Pharmaceuticals

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose

Staff, Planners, and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.


DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.


METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the online activity; and
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: May 28, 2021

EXPIRATION DATE: May 28, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].


ENDURING LEARNER NOTIFICATION

Med Learning Group
Seeing Clearer: Optimizing the Use of VEGF Inhibitors in Age-related Macular Degeneration – Enduring
Date of CE Release: May 28, 2021
Date of CE Expiration: May 28, 2022
Online

Acknowledgement of Financial Commercial Support
Regeneron

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-114-H04-P / JA4008163-9999-21-114-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives – After Attending This Program You Should Be Able To

  1. Communicate the importance of proper eye care and early intervention in preventing progressive visual changes in patients with or at risk for AMD.
  2. Incorporate collaborative strategies into clinical practice that promote team-based communication, maintain continuity of care, and improve treatment adherence for patients with or who are at risk for AMD.
  3. Identify pathogenic changes in AMD that would be best managed with a multidisciplinary approach.
  4. Evaluate clinical trial data on the efficacy and safety of currently available treatment options for the management of AMD.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below:

Name Relationship: Commercial Interest
Ana Maria Albino NA
David M. Brown Consultant: Adverum Biotechnologies, Alexion Pharmaceuticals, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Celltrion, Clearside Biomedical, Dark Horse Consulting, Horizon Therapeutics, Genentech, Kodiak Sciences, Laboratoires Théa, Lineage Cell Therapeutics (BioTime), Novartis, Ocular Therapeutix, Optos, Regeneron Pharmaceuticals, Retinal Consultants Medical Group, Senju Pharmaceutical, Verseon; Grant Recipient: Adverum Biotechnologies, Aldeyra Therapeutics, Apellis, Bayer, Bio-Imaging Resource Center (BIRC), Boehringer Ingelheim, Clearside Biomedical, Cleveland Clinic Foundation, F. Hoffmann-La Roche Limited, Gyroscope, Ionis Pharmaceuticals, Iveric Bio, Kodiak, Lowy Medical Research Institute, LumiThera, Nanoscope Therapeutics, National Eye Institute/National Institutes of Health, NGM Biopharmaceuticals, Novartis, OIRRC, Optos, Oxurion, Regeneron Pharmaceuticals, REGENXBIO, Samchundang Pharm, Santen Pharmaceutical, Senju Pharmaceuticals
Matthew Frese NA
Christina Gallo NA
Brianna Hanson NA
Nicole Longo NA
Scott McGee-Plys NA
Lauren Welch NA

How to Get Your Certificate

  1. Go to http://mlg.cmecertificateonline.com
  2. Click on “5.28.21 Seeing Clearer: Optimizing the Use of VEGF Inhibitors in Age-related Macular Degeneration – Enduring” link.
  3. Complete the post-test, click the provided link to go to the online evaluation site.
  4. Evaluate the meeting, click the provided link to open your credit certificate.
  5. Print/save all pages of your certificate for your records.

Questions?
Email [email protected]

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

Healthcare Business Review Award

We are thrilled to announce that we have been recognized as one of the Top 10 Health Education Services Providers by Healthcare Business Review!

This award is both an honor and a testament to our cumulative dedication to providing the best continuing medical education (CME) services to HCPs across the globe. We are proud to be part of this distinguished group and look forward to continuing to have MLG be one of the best CME providers in the country.

Thank you to Healthcare Business Review for this recognition and for shining a light on the importance of accurate and accessible healthcare education.

#TopHealthEducationProvider #MedLearningGroup #HealthcareBusinessReview #MedicalEducation
BestofAmerica

Best of America Small Business Awards
Best Website

The Best of America Small Business Website award recognizes the best website launched by a small business since 2021. Technology is a key growth enabler for small businesses. The best in tech track recognizes small businesses as experts in technology and innovation from innovators, app developers, and website creators. Visit our award-winning Ophthalmology and Optometry web portal: vision-relief.com

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.